Navidea Biopharmaceuticals (NYSE: NAVB)

Navidea Biopharmaceuticals is a commercial stage precision medicine company focused on the development and commercialization of precision diagnostics, therapeutics and radiopharmaceutical agents to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and therapeutics, and advancing the Company’s pipeline through global partnering and commercialization efforts. The company, founded in 1983, maintains headquarters in Dublin, Ohio and in 2012 changed its name from Neoprobe following the sale of its medical device business.

Find a broker to begin trading NAVB now

Company Name Navidea Biopharmaceuticals
Market/Symbol NYSE: NAVB
Recent Price
Market Cap $110.59M
Avg. Daily Vol. (3m) 1,792,395
Price/Book N/A
Price/Cash Flow N/A
As of Dec. 5, 2016
*Source: QuoteMedia


Begin trading NAVB

 Find Broker

Recent Company Videos


Viatar CTC: New Cancer Fighting Technology that Works Like Dialysis

Jan. 5, 2016

Viatar CTC Solutions Inc. is a medical technology company focused on the treatment of patients with metastatic cancer. The Company's lead product, the ...


Navidea Biopharmaceuticals Latest News


Ask the CEO



RedChip Direct Investment Opportunities For Private and Public Companies

Receive NAVB Email Alerts

*By entering your information you agree to our privacy policy.


"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President The NASDAQ Stock Market